Get the Stockscreener App
3.23
2.87%
0.09
After Hours:
3.30
0.07
+2.17%
Puma Biotechnology Inc stock is traded at $3.23, with a volume of 395.92K.
It is up +2.87% in the last 24 hours and up +9.49% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$3.14
Open:
$3.16
24h Volume:
395.92K
Relative Volume:
1.10
Market Cap:
$157.08M
Revenue:
$226.63M
Net Income/Loss:
$15.38M
P/E Ratio:
-64.60
EPS:
-0.05
Net Cash Flow:
$35.61M
1W Performance:
+13.73%
1M Performance:
+9.49%
6M Performance:
-19.25%
1Y Performance:
-28.06%
1-Day Range:
$3.135
$3.26
1-Week Range:
$2.792
$3.26
52-Week Range:
$2.225
$7.73
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
3.23 | 157.08M | 226.63M | 15.38M | 35.61M | -0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
Puma Biotechnology (NASDAQ:PBYI) Downgraded by StockNews.com to Buy - MarketBeat
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer - MSN
Puma commences Phase II trial of alisertib for breast cancer treatment - Clinical Trials Arena
Puma Biotech Launches Phase 2 Trial for Advanced Breast Cancer Treatment | PBYI Stock News - StockTitan
245,695 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Bought by Los Angeles Capital Management LLC - MarketBeat
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St
We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance
Puma Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Puma Biotechnology reports robust Q3 growth - Investing.com
Earnings call: Puma Biotechnology reports robust Q3 growth By Investing.com - Investing.com UK
Puma Biotechnology's (PBYI) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up - Nasdaq
Puma Biotechnology Reports Strong Q3 2024 Growth - TipRanks
Puma Biotechnology Q3 2024 Earnings Preview - MSN
Puma Biotech (PBYI) Q3 Earnings and Revenues Surpass Estimates - Yahoo Finance
Puma Biotechnology Reports Third Quarter 2024 Financial Results - sharewise
Puma Biotech: Q3 Earnings Snapshot - San Francisco Chronicle
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - sharewise
Puma Biotechnology Grants 5,625-Share Inducement Award to New Employee | PBYI | PBYI Stock News - StockTitan
Puma Biotechnology (NASDAQ:PBYI) Raised to "Strong-Buy" at StockNews.com - MarketBeat
Puma Biotechnology (PBYI) Set to Announce Quarterly Earnings on Thursday - MarketBeat
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation - GlobeNewswire
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Puma Biotechnology, Inc. (NASDAQ - The Bakersfield Californian
3 US Penny Stocks With Market Caps Under $700M - Simply Wall St
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results - BioSpace
Puma Biotechnology (NASDAQ:PBYI) Rating Increased to Strong-Buy at StockNews.com - MarketBeat
What is Zacks Research's Forecast for PBYI FY2026 Earnings? - MarketBeat
Equities Analysts Offer Predictions for PBYI Q3 Earnings - MarketBeat
With A Return On Equity Of 18%, Has Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Management Done Well? - Yahoo Finance
Puma Biotechnology quickly drops after patents for Tagrisso ruled invalid - MSN
FY2025 EPS Estimates for Puma Biotechnology, Inc. (NASDAQ:PBYI) Decreased by Zacks Research - MarketBeat
Frazier Life Sciences Management L.P. Purchases 246,264 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - MarketBeat
Affinity Asset Advisors LLC Makes New $815,000 Investment in Puma Biotechnology, Inc. (NASDAQ:PBYI) - MarketBeat
Fred Alger Management LLC Raises Stake in Hamilton Lane Incorporated (NASDAQ:HLNE) - MarketBeat
Hsbc Holdings PLC Has $4.29 Million Position in Grupo Financiero Galicia S.A. (NASDAQ:GGAL) - MarketBeat
The growth track for Humacyte Inc (HUMA) has changed recently - SETE News
Humacyte: Navigating The FDA Uncertainty And ATEV’s Potential (NASDAQ:HUMA) - Seeking Alpha
Puma VCT 13 Launches £70M Share Offer - TipRanks
HUTCHMED (NASDAQ:HCM) Shares Gap Down to $17.38 - MarketBeat
It is Poised to be a Bull Market for Puma Biotechnology Inc (PBYI) - SETE News
American Century Companies Inc. Sells 186,924 Shares of Foot Locker, Inc. (NYSE:FL) - Defense World
Bank of America Raises Trupanion (NASDAQ:TRUP) Price Target to $56.00 - MarketBeat
Achilles Thera shifts focus to new cancer treatment avenues - The Pharma Letter
Insider Selling: Sebelius Kathleen, Humacyte Inc [HUMA] Director divested 5,182 shares - Knox Daily
A$AP Rocky’s Lineup of Puma Sneakers Is Quickly Growing Bigger - Yahoo! Voices
Achilles gains on plans to explore strategic options - XM
Achilles Therapeutics Shares Are Trading Higher: What You Need To Know - Benzinga
Puma VCT 13 PLC Executes Share Buyback - TipRanks
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):